Le Lézard
Classified in: Health
Subjects: PDT, SCZ

BioPhotas, Inc. Launches the Newest Model of the Celluma Series

ANAHEIM, Calif., Jan. 3, 2018 /PRNewswire/ -- BioPhotas, Inc. announces the commercial introduction of the Celluma HOME, a fourth model in the Celluma Series of light therapy devices. Offered at an introductory price of $599.00, the Celluma HOME specifically addresses the challenges of Baby Boomers who struggle with wrinkles, aches and pain. FDA-cleared for over-the-counter purchase, the Celluma HOME treats eight separate aging challenges faced by the Baby Boomer, including full face wrinkles, arthritis, muscle and joint pain, muscle spasms and poor blood circulation.

Commenting on the launch of the Celluma HOME, Patrick Johnson, President & Chief Executive Officer for BioPhotas said, "From the very start, our goal at BioPhotas was to bring an FDA-cleared medical device directly to the consumer at home with the efficacy of large professional panels, but with the affordability of small hand-held devices. We believe we have achieved this with the Celluma HOME. Designed to treat a wide range of skin, muscle and joint conditions, anywhere on the body, the Celluma HOME gives the consumer the benefit of multiple hand-held devices in a single light panel with a significantly larger in treatment area."  

The Celluma HOME delivers blue, red and near-infrared light energy to safely address a wide variety of musculoskeletal and dermatological conditions. Each wavelength is absorbed by different molecules which act as a signaling mechanism for different cellular processes. With a treatment area that measures 14" by 6", the Celluma HOME is several times larger than typical hand-held light therapy devices. The Celluma's patented shape-taking light panel facilitates effective energy absorption by tissue by molding closely to any apart of the body, producing more efficient outcomes. 

The Celluma Series of light therapy devices is protected by both United States and Foreign utility patents and is CE-marked as a Dermal Wound Healing device. Further commenting on the launch of the Celluma HOME, Mr. Johnson noted, "[T]he Celluma HOME is a two-mode device designed specifically for the Baby Boomer who is interested in looking better and feeling better, and who wants to address those desires in the convenience of their own home." 

About BioPhotas, Inc.
In providing unique devices founded on NASA-developed technology and backed by clinical studies, BioPhotas is bringing to market safe, effective and affordable devices that unlock the clinical power of biophotonics. BioPhotas develops and markets devices for healthcare providers and consumers that conveniently treat a variety of skin, muscle and joint conditions. For more information about the Celluma please visit www.biophotas.com.

Patrick Johnson ? CEO
BioPhotas, Inc.

SOURCE BioPhotas, Inc.

These press releases may also interest you

at 20:09
A coalition of California healthcare providers and advocates has released the following statement on Friday's ruling on the Affordable Care Act: If one can take a moment to make their way through the partisanship,  the politics, and the perceptions...

at 20:05
Increased demand for medical packaging solutions in the medical packaging industry is projected to drive the overall growth of the medical packaging films market across the globe from 2018 to 2023.Read the full report:...

at 19:58
Dr. Sharon L. Van Sell is recognized by Continental Who's Who as a Pinnacle Professional in the field of Nursing in recognition of her role as Professor and Researcher at Texas Woman's University. Texas Woman's University has committed its...

at 19:15
The "Saudi Arabia Fitness Services Market Outlook to 2022 - By Revenue Stream (Gym Membership and Personal Training), by Organized and Unorganized, by Region, Gender and Membership Subscription" report has been added to ResearchAndMarkets.com's...

at 19:05
The report on the global engineered t cells market provides qualitative and quantitative analysis for the period from 2016 to 2024.Read the full report: https://www.reportlinker.com/p05657656 The report predicts the global engineered t cells market...

at 19:00
Bridge Biotherapeutics Inc., a clinical stage biotech company headquartered in Seongnam, South Korea, announced that the company signed a license agreement with Daewoong Pharmaceutical Co., Ltd. for development of BBT-401, the first anti-Pellino-1...

News published on 3 january 2018 at 15:37 and distributed by: